Buy Rating on Perspective Therapeutics: Promising Clinical Data, Strategic Advancements, and Strong Financial Position

JonesTrading analyst Justin Walsh has reiterated their bullish stance on CATX stock, giving a Buy rating on May 19.

Justin Walsh has given his Buy rating due to a combination of factors, including the promising clinical data and strategic advancements of Perspective Therapeutics. The company is set to present new data from its Pb-212-VMT-α-NET and Pb-212-VMT01 programs at the upcoming ASCO Annual Meeting, which could further validate the clinical efficacy of their lead assets.
Walsh is optimistic about the potential competitive edge of Perspective Therapeutics’ technology platforms, such as their lead-specific chelator and guest-host pretargeting approach. Additionally, the company’s strong cash position of $212 million provides a financial runway into late 2026, supporting its long-term growth and pipeline expansion. The $18 price target is supported by a risk-adjusted discounted cash flow valuation, reflecting the anticipated success and market penetration of their key programs.

In another report released on May 19, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.